A comparative approach to topical cyclosporine therapy

Area of Science:

• Veterinary Ophthalmology
• Immunology
• Pharmacology

Background:

• Topical cyclosporine has been a veterinary ophthalmology staple since 1989 for ocular surface inflammatory diseases and keratoconjunctivitis sicca (KCS).
• It ameliorates clinical signs of ocular surface lymphocyte-driven inflammation in dogs, cats, and horses.
• Cyclosporine significantly increases tear production in both normal and KCS-affected animals.

Purpose of the Study:

• To examine the mechanisms of cyclosporine's immunomodulatory and lacrimogenic actions.
• To investigate the pharmacokinetics of topical cyclosporine to determine if effects are local or due to systemic absorption.
• To review side effects of cyclosporine preparations in veterinary ophthalmology.

Main Methods:

• Review of existing literature on topical cyclosporine use in veterinary ophthalmology.
• Examination of experimental evidence regarding cyclosporine's mechanisms of action.
• Analysis of pharmacokinetic data to assess systemic absorption.

Main Results:

• Topical cyclosporine demonstrates both immunomodulatory and lacrimogenic effects.
• Evidence suggests that side effects are more likely attributable to the vehicle than cyclosporine.
• Pharmacokinetic data are analyzed to differentiate local versus systemic effects.

Conclusions:

• Topical cyclosporine is a valuable ophthalmic preparation in veterinary medicine, effectively treating ocular inflammation and increasing tear production.
• The drug's mechanisms of action involve both immune modulation and stimulation of lacrimation.
• Further investigation into its use in human ophthalmology is warranted given its success in veterinary patients.